Equity research analysts covering Keros Therapeutics provide consensus twelve-month price targets that fluctuate depending on recent clinical trial updates, macroeconomic shifts, and broader market conditions affecting the biotechnology sector. Financial tracking platforms compiling projections from healthcare analysts indicate that average price targets generally suggest potential upside from its trading baseline, reflecting confidence in its proprietary protein-engineering platform and pipeline milestones. However, individual analyst targets vary widely, reflecting the inherent unpredictability and high-risk nature associated with clinical-stage drug development companies.